Premium
Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor‐binding domain mutations: Receptor affinity versus neutralization of receptor interaction
Author(s) -
Vogel Monique,
Augusto Gilles,
Chang Xinyue,
Liu Xuelan,
Speiser Daniel,
Mohsen Mona O.,
Bachmann Martin F.
Publication year - 2022
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.15002
Subject(s) - receptor , mutation , mutant , neutralization , antibody , immune system , biology , coronavirus , microbiology and biotechnology , virology , gene , genetics , covid-19 , medicine , disease , infectious disease (medical specialty)
Background Several new variants of SARS‐CoV‐2 have emerged since fall 2020 which have multiple mutations in the receptor‐binding domain (RBD) of the spike protein. It is unclear which mutations affect receptor affinity versus immune recognition. Methods We produced wild type RBD, RBD with single mutations (E484K, K417N, or N501Y) or with all three mutations combined and tested their binding to ACE2 by biolayer interferometry (BLI). The ability of convalescent sera to recognize RBDs and block their interaction with ACE2 was tested as well. Results We demonstrated that single mutation N501Y increased binding affinity to ACE2 but did not strongly affect its recognition by convalescent sera. In contrast, single mutation E484K had almost no impact on the binding kinetics, but essentially abolished recognition of RBD by convalescent sera. Interestingly, combining mutations E484K, K417N, and N501Y resulted in a RBD with both features: enhanced receptor binding and abolished immune recognition. Conclusions Our data demonstrate that single mutations either affect receptor affinity or immune recognition while triple mutant RBDs combine both features.